Background:
Stereotactic Body Radiation Therapy (SBRT) is used to treat cancers using substantially higher doses of radiation than conventional radiotherapy. This technology is able to deliver higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues.
The drugs used in this study are Ipilimumab (Yervoy®) and Nivolumab (Opdivo®), which are immunotherapy drugs that work by reactivating the body’s own immune response to target and destroy cancer cells. In combination, Ipilimumab and Nivolumab are Health Canada-approved for the treatment of advanced kidney cancer.
The Trial:
This study will investigate the safety and effectiveness of combining SBRT with Ipilimumab and Nivolumab. Specifically, the researchers will test whether SBRT can improve a patient’s response to treatment with Ipilimumab and Nivolumab.
Patients on this trial will be randomly assigned to one of two groups:
1. Ipilimumab and Nivolumab only
2. SBRT followed by Ipilimumab and Nivolumab
Basic Eligibility:
- All subtypes eligible
- No prior systematic therapy is permitted
- Cancer must have spread beyond the kidney
- Cancer cannot be removed by surgery
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
---|---|---|---|
Hospital / Cancer CentreCross Cancer Institute | Principal InvestigatorDr. Naveen Basappa | LocationEdmonton, AB | Trial StatusRecruiting |
Hospital / Cancer CentreLondon Regional Cancer Centre | Principal InvestigatorDr. Eric Winquist | LocationLondon, ON | Trial StatusWithdrawn |
Hospital / Cancer CentreGrand River Regional Cancer Centre | Principal InvestigatorDr. Darin Gopaul | LocationKitchener, ON | Trial StatusRecruiting |
Hospital / Cancer CentreJuravinski Cancer Centre | Principal InvestigatorDr. Aly-Khan Lalani | LocationHamilton, ON | Trial StatusRecruiting |
Hospital / Cancer CentreSunnybrook Health Sciences Centre- Odette Cancer Centre | Principal InvestigatorDr. William Chu | LocationToronto, ON | Trial StatusRecruiting |
Hospital / Cancer CentreThe Ottawa Regional Cancer Centre | Principal InvestigatorDr. Scott Morgan | LocationOttawa, ON | Trial StatusRecruiting |
Hospital / Cancer CentreMcGill University Health Centre - Glen site | Principal Investigator | LocationMontréal, QC | Trial StatusRecruiting |